<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">Baloxavir Marboxil was approved by FDA in October 2018 for use in patients with uncomplicated influenza aged above 12 y and weighing above 40 kg, who present within 48 h of onset of illness [
 <xref ref-type="bibr" rid="CR21">21</xref>]. This oral antiviral inhibits viral replication by targeting the endonuclease function encoded by the polymerase acidic subunit of the viral polymerase. It has shown broad antiviral activity against all known types of Influenza (A, B, C and D) and the Influenza A viruses of avian and swine origin which have the potential to cause pandemic [
 <xref ref-type="bibr" rid="CR22">22</xref>].
</p>
